Finch Therapeutics Group (FNCH) Competitors $12.03 -0.10 (-0.82%) As of 10:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. OKYO, RPTX, UNCY, CRVO, SLGL, JATT, VTVT, PMVP, BYSI, and HYPDShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include OKYO Pharma (OKYO), Repare Therapeutics (RPTX), Unicycive Therapeutics (UNCY), CervoMed (CRVO), Sol-Gel Technologies (SLGL), JATT Acquisition (JATT), vTv Therapeutics (VTVT), PMV Pharmaceuticals (PMVP), BeyondSpring (BYSI), and Hyperion DeFi (HYPD). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors OKYO Pharma Repare Therapeutics Unicycive Therapeutics CervoMed Sol-Gel Technologies JATT Acquisition vTv Therapeutics PMV Pharmaceuticals BeyondSpring Hyperion DeFi OKYO Pharma (NASDAQ:OKYO) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Does the media prefer OKYO or FNCH? In the previous week, OKYO Pharma and OKYO Pharma both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.43 beat Finch Therapeutics Group's score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OKYO or FNCH more profitable? OKYO Pharma's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Finch Therapeutics Group N/A -69.14%-26.92% Do analysts rate OKYO or FNCH? OKYO Pharma currently has a consensus price target of $7.00, indicating a potential upside of 244.83%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, OKYO or FNCH? OKYO Pharma has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Do insiders & institutionals hold more shares of OKYO or FNCH? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, OKYO or FNCH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$4.71MN/AN/AFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.36 SummaryOKYO Pharma beats Finch Therapeutics Group on 7 of the 10 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.32M$354.53M$6.10B$10.53BDividend YieldN/AN/A5.51%4.66%P/E Ratio-1.36N/A85.6826.85Price / SalesN/A436.13584.82185.94Price / CashN/A22.4426.3031.10Price / Book0.843.8513.256.72Net Income-$74.75M-$133.30M$3.30B$276.44M7 Day Performance-2.04%5.53%4.70%3.13%1 Month PerformanceN/A21.35%8.43%10.21%1 Year Performance4.61%19.48%88.01%40.35% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group0.8057 of 5 stars$12.03-0.8%N/A+3.8%$19.32MN/A-1.36190News CoverageOKYOOKYO Pharma2.8754 of 5 stars$2.02+0.8%$7.00+247.4%+90.7%$75.78MN/A0.007Short Interest ↓RPTXRepare Therapeutics2.8159 of 5 stars$1.76flat$4.50+155.7%-50.9%$75.61M$250K-0.68180News CoveragePositive NewsUNCYUnicycive Therapeutics2.3265 of 5 stars$4.27-2.1%$57.00+1,234.9%+23.1%$75.41M$680K-1.049CRVOCervoMed3.6845 of 5 stars$8.12+0.4%$19.29+137.5%-39.9%$75.11M$9.74M-3.114News CoverageShort Interest ↓SLGLSol-Gel Technologies0.332 of 5 stars$26.88-6.5%N/A+550.0%$74.89M$23.93M-21.8550News CoverageGap DownTrading HaltedJATTJATT AcquisitionN/A$4.33+44.8%N/A-10.3%$74.69MN/A0.003News CoverageHigh Trading VolumeVTVTvTv Therapeutics1.7133 of 5 stars$23.07+0.5%$35.50+53.9%+54.8%$74.39M$17K-7.469PMVPPMV Pharmaceuticals2.7295 of 5 stars$1.39-1.1%$5.50+297.1%-4.6%$73.39MN/A-0.8850BYSIBeyondSpringN/A$1.82+0.3%N/A-24.9%$73.20MN/A0.0080Positive NewsHYPDHyperion DeFi0.5851 of 5 stars$10.51+9.7%$2.00-81.0%-73.1%$73.14M$44.44K-0.1840 Related Companies and Tools Related Companies OKYO Alternatives RPTX Alternatives UNCY Alternatives CRVO Alternatives SLGL Alternatives JATT Alternatives VTVT Alternatives PMVP Alternatives BYSI Alternatives HYPD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
